HALO insider trading
NasdaqGS HealthcareHALOZYME THERAPEUTICS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About HALOZYME THERAPEUTICS, INC.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Company website: halozyme.com
HALO insider activity at a glance
FilingIQ has scored 912 insider transactions for HALO since Jan 17, 2015. The most recent filing in our index is dated May 13, 2026.
Across the full history, 5 open-market purchases
and 321 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on HALO insider trades is 57.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest HALO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading HALO
13F funds holding HALO
Politicians who have traded HALO
Frequently asked
- How many insider trades does FilingIQ track for HALO?
- FilingIQ tracks 912 Form 4 insider transactions for HALO (HALOZYME THERAPEUTICS, INC.), covering filings from Jan 17, 2015 onwards. 109 of those were filed in the last 90 days.
- Are HALO insiders net buyers or net sellers?
- Across the full Form 4 history for HALO, 5 transactions (1%) were open-market purchases and 321 (35%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does HALO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is HALO in?
- HALOZYME THERAPEUTICS, INC. (HALO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $8.34B.
Methodology & sources
Every HALO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.